- Home
- NRXP vs CTSO Comparison
NRXP vs CTSO Comparison
Compare NRXP & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | CTSO |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 45.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NRXP | CTSO |
|---|---|---|
| Price | $2.26 | $0.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $30.50 | $5.38 |
| AVG Volume (30 Days) | ★ 422.2K | 126.1K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $242,000.00 | ★ $36,979,520.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | $643.59 | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $1.15 | $0.60 |
| 52 Week High | $6.01 | $1.61 |
Technical Indicators
Market Signals| Indicator | NRXP | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 47.96 |
| Support Level | $2.22 | $0.70 |
| Resistance Level | $2.51 | $0.75 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 48.15 | 56.00 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.